Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
83.3%
-
Total 13F principal
-
$606,758,832
-
Principal change
-
+$24,279,664
-
Total reported market value
-
$506,221,139
-
Number of holders
-
64
-
Value change
-
+$19,224,781
-
Number of buys
-
28
-
Number of sells
-
23
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2023
As of 30 Jun 2023,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
64 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$606,758,832
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, CAMDEN ASSET MANAGEMENT L P /CA, Invesco Ltd., Wellesley Asset Management, Linden Advisors LP, DAVIDSON KEMPNER CAPITAL MANAGEMENT LP, CITIGROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, AVIVA PLC, and AMERIPRISE FINANCIAL INC.
This page lists
67
institutional bondholders reporting positions
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.